Cargando…
Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
OBJECTIVES: To determine the long-term effects of delayed-release cysteamine bitartrate (DR-CYS) based on our previous work that established the short-term noninferiority of DR-CYS every 12 hours compared with immediate-release cysteamine bitartrate every 6 hours. STUDY DESIGN: We conducted a prospe...
Autores principales: | Langman, Craig B., Greenbaum, Larry A., Grimm, Paul, Sarwal, Minnie, Niaudet, Patrick, Deschenes, Georges, Cornelissen, Elisabeth A. M., Morin, Denis, Cochat, Pierre, Elenberg, Ewa, Hanna, Christian, Gaillard, Segolene, Bagger, Mary Jo, Rioux, Patrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181581/ https://www.ncbi.nlm.nih.gov/pubmed/24948347 http://dx.doi.org/10.1016/j.jpeds.2014.05.013 |
Ejemplares similares
-
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011) -
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023) -
Response to Cysteamine in Osteoclasts Obtained from Patients with Nephropathic Cystinosis: A Genotype/Phenotype Correlation
por: Quinaux, Thomas, et al.
Publicado: (2021) -
Cysteamine bitartrate delayed‐release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open‐label study of treatment‐naïve patients <6 years of age with nephropathic cystinosis
por: Vaisbich, Maria Helena, et al.
Publicado: (2021)